<DOC>
	<DOCNO>NCT00995514</DOCNO>
	<brief_summary>The primary objective trial demonstrate non-inferiority clopidogrel compare prasugrel 6 month cardiovascular disease patient clopidogrel cohort limit estimate 70 % population CYP2C19 extensive metabolizers . This protocol examine comparative effectiveness two strategy .</brief_summary>
	<brief_title>Genotype Guided Comparison Clopidogrel Prasugrel Outcomes Study</brief_title>
	<detailed_description>This prospective , non-randomized , open-label , non-inferiority comparative effectiveness outcomes trial compare clopidogrel EMs ( confirm CYP2C19 genotype ) receive clopidogrel 75 mg/day subject receive prasugrel 5 and/or 10 mg/day . The antiplatelet drug clopidogrel commonly prescribe therapy patient follow ACS , stroke , PCI without stent placement , patient peripheral artery disease . However , recent research suggest vitro anti-platelet response clopidogrel may limit lose 30 % treated individual , may associate inferior clinical outcome . The antiplatelet effect clopidogrel require conversion parent compound active thiol . This active thiol metabolite inhibits adenosine diphosphate ( ADP ) -induced platelet aggregation block platelet P2Y12 receptor , result reduction ADP-mediated platelet aggregation . Conversion clopidogrel active metabolite relatively inefficient process 85 % pro-drug converted inactive metabolite esterases , remain 15 % oxidized active form cytochrome P-450 ( CYP ) enzymes . The variability clopidogrel response associate variability CYP enzyme genetic expression activity , primarily CYP2C19 principally responsible conversion clopidogrel active metabolite . CYP2C19 genetically polymorphic , allele produce reduce enhanced drug metabolism . These polymorphisms include loss-of-function allele CYP2C19 *2 , *3 , *4 *5 ultra-rapid metabolizer CYP2C19 *17 . Subjects carry wild-type allele CYP2C19 ( *1/*1 extensive metabolizers , EM ) able efficiently metabolize clopidogrel great exposure active metabolite , well high level platelet inhibition follow clopidogrel exposure . Intermediate metabolizers ( IM ) , individual carry one reduce function allele ( e.g . *1/*2 , *1/*3 , etc ) , circulate active drug metabolite level reduce 30 % compare EMs result 25 % reduction platelet inhibition . These result consistent study also demonstrate individual carry CYP2C19*2 allele decrease level platelet aggregation inhibition follow clopidogrel administration compare *1/*1 wild type . A series recent article explore effect genetic polymorphism CYP2C19 anti-platelet activity clopidogrel well clinical outcome follow PCI . Collett , et al . examine 259 patient &lt; 45 year age treat clopidogrel follow MI . Carriers CYP2C19*2 allele increase incidence death , MI urgent coronary revascularization ( p=0.0005 , HR = 3.69 ) . Simon , et al . examine 2,208 patient present acute MI receive clopidogrel therapy find individual carry one CYP2C19 loss-of-function allele ( ) high rate cardiovascular event non-carriers . The risk death , non-fatal MI cardiovascular stroke 1 year PCI 3.58 time great patient carry two loss-of-function allele compare wild-type patient . Trenk , et al. , associate elevated platelet activity poor clinical outcome patient the*2 allele 797 patient follow one year PCI . Prasugrel third generation thienopyridine , appear increased antiplatelet efficacy compare clopidogrel . Like clopidogrel , prasugrel pro-drug require metabolic activation . However , esterases know inactivate clopidogrel act prasugrel prime activation single CYP-dependant oxidation step . This direct pathway result efficient activation pathway prasugrel . The efficacy prasugrel clopidogrel compare head-to-head TRITON-TIMI 38 study . This trial enrol 13,608 ACS patient schedule PCI compare prasugrel ( 60-mg loading dose 10-mg daily maintenance dose ) clopidogrel ( 300-mg/75-mg ) , combination aspirin . Results indicate prasugrel reduce combined rate death cardiovascular cause , nonfatal myocardial infarction , nonfatal stroke ( 12.1 % clopidogrel vs. 9.9 % prasugrel ) 15 month post-ACS . These favorable effect cardiovascular event offset increased rate serious bleeding ( 1.4 % , vs. 0.9 % clopidogrel group ) fatal bleeding ( 0.4 % vs. 0.1 % ) . Overall mortality differ two treatment group . A genetic substudy subsequently publish Mega , et al . examine association CYP2C19 genotypes cardiovascular outcome subset 1,477 clopidogrel-treated subject enrol TRITON-TIMI 38 study . This study demonstrate carrier one reduced-function CYP2C19 alleles 53 % increase composite primary efficacy outcome compare non-carriers ( 12.1 % vs 8.0 % , p=0.01 ) 15 month follow-up . In contrast , outcomes subset prasugrel-treated patient similar across CYP2C19 genotype . Unfortunately , in-trial response clopidogrel among genetic substudy participant differ overall clopidogrel study cohort , thus prevent direct comparison clopidogrel prasugrel function CYP2C19 genotype On March 12 , 2010 FDA add Boxed Warning Plavix prescribe information . The Boxed Warning concern patient effectively metabolize drug ( i.e . `` poor metabolizers '' ) therefore may receive full benefit drug . This label modification affirms impact CYP2C19 genotype pharmacokinetics clopidogrel 's active metabolite , importantly , confirm effect reduce anti-platelet response high rate cardiovascular event IM PM population . The event rate clopidogrel extensive metabolizers alone never directly compare prasugrel . Upon review data extract Medco 's integrated claim database , `` real-world '' prescribe practice physician Plavix Effient vary significantly narrow indication ACS study TRITON-TIMI 38 study , current Effient approve label . Only 27 % patient new Plavix therapy experience ACS event within 6 month new prescription . Similarly , 13 % new Effient user evidence ACS event within 6 month new prescription agent . Overall , approximately Â½ new Plavix user 80 % new Effient user evidence hospitalization event ACS , stroke , percutaneous coronary intervention , peripheral arterial disease , indicate instead stable cardiovascular disease . These data justify expand entry criterion GeCCO study include patient recent prescription clopidogrel prasugrel without precipitate ACS event . The purpose study compare outcomes cardiovascular disease patient prescribe Plavix Effient real-world population . If , case , population receive drug include significant number patient either without recent hospitalization ACS and/or stable coronary disease , population GeCCO study may justifiably expand include new indication . This afford opportunity fulfill comparative effectiveness research intent investigation outcomes therapy utilized physician clinic setting .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>Men woman 18 year 75 year age Recent prescription clopidogrel prasugrel . Participant willing able provide inform consent . Previous use thienopyridine within 4 month initiate new clopidogrel prasugrel therapy . Participant refusal participate study . Anticipated discontinuation clopidogrel prasugrel within 6 month study followup period Participants previously state `` contact ''</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>acute coronary syndrome</keyword>
	<keyword>cardiovascular death</keyword>
	<keyword>non-fatal MI</keyword>
	<keyword>non-fatal stroke</keyword>
	<keyword>genetic testing</keyword>
	<keyword>CYP2C19</keyword>
	<keyword>clopidogrel</keyword>
	<keyword>prasugrel</keyword>
	<keyword>antiplatelet therapy</keyword>
	<keyword>genotyping</keyword>
	<keyword>bleeding</keyword>
</DOC>